-
1.发明授权Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 失效调节，抑制或调节结缔组织生长因子（CTGF）的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病变的独特手段的药剂公开(公告)号：US07351407B2
公开(公告)日：2008-04-01
申请号：US10510585
申请日：2003-04-18
IPC分类号： A61K31/74
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
公开(公告)号：US20060172965A1
公开(公告)日：2006-08-03
申请号：US11345361
申请日：2006-02-01
申请人： Allan Shepard , Jon Chatterton , Abbot Clark , Martin Wax
发明人： Allan Shepard , Jon Chatterton , Abbot Clark , Martin Wax
IPC分类号： A61K48/00
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + + / K + + -ATP酶; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
公开(公告)号：US20060166919A1
公开(公告)日：2006-07-27
申请号：US11313200
申请日：2005-12-19
申请人： Allan Shepard , Iok-Hou Pang
发明人： Allan Shepard , Iok-Hou Pang
IPC分类号： A61K48/00
CPC分类号： C12N15/1136 , A61K31/713 , C12N15/111 , C12N2310/14 , C12N2320/32
摘要： RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
-
4.发明申请Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 失效调节，抑制或调节结缔组织生长因子（ctgf）的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病的独特手段的药剂公开(公告)号：US20050234075A1
公开(公告)日：2005-10-20
申请号：US10510585
申请日：2003-04-18
申请人： Debra Fleenor , Allan Shepard , Nasreen Jacobson , Iok-Hou Pang , Abbot Clark
发明人： Debra Fleenor , Allan Shepard , Nasreen Jacobson , Iok-Hou Pang , Abbot Clark
IPC分类号： A61F9/007 , A61K31/00 , A61K31/202 , A61K31/404 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/519 , A61K31/52 , A61K45/00 , A61P27/02 , A61P27/06 , C12N9/99
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
5.发明申请PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA 审中-公开用于高血压控制和GLAUCOMA治疗的PRENYLTRANSFERASE抑制剂公开(公告)号：US20070232675A1
公开(公告)日：2007-10-04
申请号：US11692316
申请日：2007-03-28
申请人： Allan Shepard , Debra Fleenor
发明人： Allan Shepard , Debra Fleenor
IPC分类号： A61K31/4172 , A61K31/195 , A61K31/557 , A61K31/24
CPC分类号： A61K31/166 , A61K31/195 , A61K31/24 , A61K31/417 , A61K31/4172 , A61K31/4178 , A61K31/4709 , A61K31/557
摘要： The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.
摘要翻译： 本发明在一个实施方案中涉及治疗青光眼或升高的眼内压的方法，其包括施用药学有效量的包含至少一种异戊烯基转移酶抑制剂的组合物。 在另一个实施方案中，本发明涉及用于治疗眼内压升高和青光眼的组合物，其包含药学有效量的异戊烯基转移酶抑制剂。
-
6.发明申请C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H 审中-公开用于预防和治疗患有年龄相关性黄斑变性的C3-转化酶抑制剂在患有风险变异的补体因子H公开(公告)号：US20070149616A1
公开(公告)日：2007-06-28
申请号：US11614595
申请日：2006-12-21
申请人： Abbot Clark , Allan Shepard
发明人： Abbot Clark , Allan Shepard
IPC分类号： A61K31/235 , C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/215 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.
摘要翻译： 本发明提供了通过鉴定补体H基因中存在Y402H多态性或其它风险变体的方法来鉴定患有发展AMD风险的患者的方法。 本发明进一步提供了治疗患有AMD的患者或由于在补体H基因中具有Y402H多态性或其他风险变异体而发展为AMD的风险的患者的方法。
-
公开(公告)号：US20070142376A1
公开(公告)日：2007-06-21
申请号：US11611312
申请日：2006-12-15
申请人： Debra FLEENOR , Iok-Hou PANG , Allan SHEPARD , Mark HELLBERG , Abbot CLARK , Peter KLIMKO
发明人： Debra FLEENOR , Iok-Hou PANG , Allan SHEPARD , Mark HELLBERG , Abbot CLARK , Peter KLIMKO
IPC分类号： A61K31/5377 , A61K31/506 , A61K31/519 , A61K31/4745 , A61K31/4709 , A61K31/4439 , A61K31/444
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
8.发明申请Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 审中-公开调节，抑制或调节赖氨酰氧化酶（LOX）和LOX样蛋白酶的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病的独特手段的药剂公开(公告)号：US20060134172A1
公开(公告)日：2006-06-22
申请号：US11293924
申请日：2005-12-05
申请人： Allan Shepard , Abbot Clark , Mark Hellberg
发明人： Allan Shepard , Abbot Clark , Mark Hellberg
IPC分类号： A61F2/00
CPC分类号： A61K31/135 , A61F9/0008 , A61K31/275 , A61K31/381
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制赖氨酰氧化酶（LOX）的表达和/或信号传递的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法， 或赖氨酰氧化酶样蛋白酶（LOXL）。
-
公开(公告)号：US20060020001A1
公开(公告)日：2006-01-26
申请号：US10537052
申请日：2003-12-19
申请人： Allan Shepard , Abbot Clark , Nasreen Jacobson
发明人： Allan Shepard , Abbot Clark , Nasreen Jacobson
IPC分类号： A61K31/426
CPC分类号： A61K31/426 , A61K31/165
摘要： Compositions containing inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compositions of the invention are further provided.
摘要翻译： 提供含有组织蛋白酶K（CTSK）表达和/或活性抑制剂的组合物。 进一步提供使用本发明组合物治疗青光眼的方法。
-
公开(公告)号：US20050239871A1
公开(公告)日：2005-10-27
申请号：US11114512
申请日：2005-04-25
申请人： Mark Hellberg , Debra Fleenor , Allan Shepard , Iok-Hou Pang
发明人： Mark Hellberg , Debra Fleenor , Allan Shepard , Iok-Hou Pang
IPC分类号： A61K9/00 , A61K31/00 , A61K31/225 , A61K31/366 , A61K31/401
CPC分类号： A61K31/00 , A61K31/225 , A61K31/366 , A61K31/401
摘要： The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.
摘要翻译： 描述了使用HMG-CoA还原酶抑制剂（例如他汀类药物）来治疗青光眼，控制眼内压，保留小梁网，防止眼神经变性和/或防止青光眼性视网膜病变。 优选的HMG-CoA还原酶抑制剂，其为RI值为0.2至0.7的他汀类（例如，普伐他汀），通过局部施用施用于患者的受影响的眼睛。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.017 秒)
